Mark Zuckerberg and Priscilla Chan are shifting their philanthropic focus toward using artificial intelligence (AI) to tackle diseases. Their organization, the Chan Zuckerberg Initiative (CZI), is now unifying its scientific efforts under a new name, Biohub. This initiative aims to leverage AI to expedite medical research and discoveries. CZI has acquired EvolutionaryScale, an AI research lab specializing in life sciences, although the financial details of the acquisition remain undisclosed. Chan emphasized their intention to foster a broad scientific inquiry rather than targeting specific diseases. Her personal motivation stems from a childhood experience with loss, which drove her to learn about oncology. The couple believes that advancements in AI can create digital models of biological processes, potentially revolutionizing the way scientists approach disease prevention and treatment. They assert that rapid advancements in AI could lead to significant breakthroughs in understanding and curing diseases. However, this pivot has drawn criticism, particularly from communities that previously benefited from CZI's education and health initiatives. Notably, a school in East Palo Alto that offered comprehensive support to students and families is set to close at the end of the 2025-26 school year. Despite the pushback, Zuckerberg and Chan remain optimistic about their ambitious goal of curing all diseases, arguing that the potential of AI could make this vision attainable sooner than many expect.